Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Pmv Pharmaceuticals Inc (PMVP)

68 + Investors. Track Smart Money conviction in PMVP. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +6
Streak
1Q ▲
Buyers last Q
52%

Smart Money Signals — PMVP

Based on 68 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds added PMVP than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🔻

Below peak — only 67% of 3.0Y high

67% of all-time peak
Only 68 funds hold PMVP today versus a peak of 101 funds at 2023 Q2 — just 67% of the maximum. Low institutional ownership can mean the stock is out of favor, but it also means there's a large pool of potential buyers if sentiment turns.
🚀

Fast accumulation — +26% more funds vs a year ago

fund count last 6Q
+14 new funds entered over the past year (+26% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 52% buying

31 buying29 selling
Last quarter: 31 funds bought or added vs 29 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
➡️

Steady new buyers — ~15 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 7 → 20 → 10 → 15. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

54% of holders stayed for 2+ years

■ 54% conviction (2yr+) ■ 24% medium ■ 22% new
37 out of 68 hedge funds have held PMVP for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
➡️

Steady discovery — ~15 new funds/quarter

1 → 7 → 20 → 10 → 15 new funds/Q
New funds entering each quarter: 7 → 20 → 10 → 15. Consistent flow of new institutional buyers without clear acceleration or slowdown.
🏛️

Veteran-anchored — 64% veterans vs 23% newcomers

■ 64% veterans ■ 13% 1-2yr ■ 23% new
Entry-cohort mix of 69 holders: 44 (64%) are 2+ year veterans, 9 entered 1–2 years ago, and 16 (23%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
📋

Smaller funds dominant — 7% AUM from top-100

7% from top-100 AUM funds
18 of 68 holders rank in the top 100 by AUM, but together hold only 7% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
2.2
out of 10
Low Exit Risk
Exit risk score 2.2/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — PMVP

In 2026 Q1, 31 hedge funds were net buyers of PMVP (15 opened a new position, 16 added to an existing one), while 29 reduced or exited (20 trimmed, 9 sold completely) — a 52% buyer ratio, indicating a slight buying edge. Net fund flow last quarter: +6 funds (more new holders than closures). Total institutional holders: 68.

Hedge Fund Ownership: PMVP

How many hedge funds hold PMVP — quarterly history vs. share price
Quarterly hedge fund ownership of PMVP vs. share price

Market Analysis: PMVP

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: PMVP

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Pmv Pharmaceuticals Inc (PMVP) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much PMVP has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 77d ago
PMVP
-12.9%
XLV
+4.3%

PMVP outperformed XLV by -17.2% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 32d ago
PMVP
-16.3%
XLV
+5.4%

Since the filing became public, PMVP outperformed XLV by -21.7% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

7 top-rated funds 1 high-conviction
Consensus
3.9
/ 10
breadth
×
Elite
2.0
/ 10
conviction
Hedge Fund Positioning: PMVP
68 + Investors

Track Smart Money conviction in PMVP. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 68 62 9.68%
13F Shares 38M 37M 1.22%
Total Value $44M $47M -5.61%
New Positions 15 10 +5
Increased Positions 15 22 -7
Closed Positions 9 11 -2
Reduced Positions 20 17 +3
Total Calls 1 1 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: PMVP

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

68 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in PMVP. Verified SEC 13F-HR filings.

QUARTER:
Top 25 PMVP holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 BML Capital Management, LLC 4.24% 5,320,000 $6.6M
2 Euclidean Capital LLC 0.83% 2,627,643 $3.3M
3 Sio Capital Management, LLC 0.55% 3,076,580 $3.8M
4 Aldebaran Capital, LLC 0.45% 473,362 $587K
5 Stonepine Capital Management, LLC 0.35% 708,102 $878K
6 Tang Capital Management LLC 0.27% 4,245,085 $5.3M
7 Verdad Advisers, LP 0.25% 180,161 $223K
8 Eversept Partners, LP 0.15% 2,348,360 $2.9M
9 ArrowMark Colorado Holdings LLC 0.09% 2,872,764 $3.6M
10 Rangeley Capital, LLC 0.08% 66,846 $83K
11 Velan Capital Investment Management LP 0.06% 73,000 $91K
12 Longaeva Partners L.P. 0.03% 552,027 $685K
13 Seven Fleet Capital Management LP 0.02% 63,498 $79K
14 ADAR1 Capital Management, LLC 0.02% 231,008 $286K
15 Bridgeway Capital Management, LLC 0.01% 428,853 $532K
16 RBF Capital, LLC 0.01% 162,200 $201K
17 Ikarian Capital, LLC 0.01% 89,136 $111K
18 Accurate Wealth Management, LLC 0.01% 50,000 $66K
19 BIT Capital GmbH 0.01% 123,555 $153K
20 Silver Grove Financial Group, Inc. 0.01% 5,082 $6K
21 Adage Capital Partners GP, L.L.C. 0.00% 1,860,000 $2.3M
22 Evoke Wealth, LLC 0.00% 133,122 $165K
23 Two Sigma Advisers, LP 0.00% 874,100 $1.1M
24 Two Sigma Investments, LP 0.00% 1,884,530 $2.3M
25 Walleye Capital LLC 0.00% 335,694 $416K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Pmv Pharmaceuticals Inc (PMVP)

What does the Smart Money Trend signal show for PMVP?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added PMVP than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for PMVP?

Slight buying edge — 52% buying: Last quarter: 31 funds bought or added vs 29 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for PMVP holders?

Smaller funds dominant — 7% AUM from top-100: 18 of 68 holders rank in the top 100 by AUM, but together hold only 7% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held PMVP?

54% of holders stayed for 2+ years: 37 out of 68 hedge funds have held PMVP for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Pmv Pharmaceuticals Inc (PMVP) following the 2026 Q1 hedge fund 13F filings?

As of today, PMVP has moved -16.3% since the 2026 Q1 13F filing date (May 15, 2026), compared to +5.4% for the XLV sector ETF — an outperformance of -21.7%. Since the quarter end (March 31, 2026), PMVP has gained -12.9% vs +4.3% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →